

Expansion of Tumor-Infiltrating Lymphocytes (TIL) Using Static Bag for the Clinical Manufacturing Rapid Expansion Protocol (REP) Process

Kenneth Onimus, Adrian Wells, Nermin Gerges, Courtney Herman, Viktoria Gontcharova, Joe Wypych, Arvind Natarajan, Anand Veerapathran

Iovance Biotherapeutics, Inc., 999 Skyway Road, Suite 150, San Carlos, CA 94070



For more information, please contact
Anand Veerapathran
Anand.Veerapathran@iovance.com

Introduction

Background


- Lifileuceal (LN-144) and LN-145, adoptive cell therapies using autologous tumor-infiltrating lymphocytes (TIL), have demonstrated encouraging efficacy with acceptable safety in a variety of tumor types and settings¹⁻⁴
- The lifileuceal Gen 2 clinical manufacturing process uses gas-permeable rapid expansion bioreactors (G-Rex®, Wilson Wolf, Saint Paul, MN) for TIL expansion
- Static gas-permeable cell culture bags (EXP-Pak™, Charter Medical, Winston-Salem, NC) are alternate bioreactors that have been used for clinical manufacturing of T-cells
- TIL product characteristics were compared after expansion at small- and full-scale using G-Rex bioreactors and EXP-Pak bags

Study Objectives

- To determine the feasibility of using static gas-permeable cell culture bags to expand TIL for the clinical manufacturing rapid expansion protocol (REP) process
- To characterize the final harvested product for the following quality attributes:
 - Dose: Cell count and % viability
 - Identity: % CD45⁺CD3⁺ T-cells
 - Potency: Ability to secrete IFN γ in response to stimulation with anti-CD3, -CD28, and -CD137
 - Phenotype: Memory, activation, exhaustion, and impurity status
 - Reduction/Oxidation (REDOX) Potential: TIL proliferation capacity, metabolic by-products, apoptosis, cell-cycle analysis, and mitochondrial function
 - T-cell Receptor (TCR) Clonotypes: Unique CDR3 counts and shared clones of TCR repertoire

Proposed TIL Manufacturing Process Using EXP-Pak Bags

Figure 1. Gen 2 TIL Manufacturing Process and Experiment Design



Methods

Manufacturing

- Cryopreserved pre-REP TIL were cultured with OKT-3 and irradiated peripheral blood mononuclear cells in small-scale (G-Rex 5M flasks or EXP-50 bags) or full-scale (G-Rex 500MCS or EXP-5L bags) conditions using the same culture media formulation throughout the 22-day process (Figure 1)

Dose

- Final harvested TIL and in-process samples were assayed for total nucleated cells, total viable cells, and viability determined by acridine orange / DAPI counterstain using the NucleoCounter® NC-200™ (ChemoMetec, Lillerød, Denmark) automated cell counter

Identity

- Final harvested TIL products were sampled and assayed for identity by flow cytometry staining
- Percent T-cells was determined as the percentage of CD45⁺CD3⁺ (double positive) population of viable cells

Potency

- The ability of the harvested TIL product to secrete IFN γ upon reactivation was measured following coculture with antibody-coated beads (anti-CD3, -CD28, and -CD137; ThermoFisher, Waltham, MA)
- After 24 hours of co-culture, culture supernatants were harvested, frozen, thawed, and assayed by ELISA
- Quantikine® IFN γ ELISA kit (R&D Systems, Minneapolis, MN) was used to measure IFN γ in the supernatant

Phenotype

- Final harvested TIL products were thawed and assayed for extended phenotypic markers using two flow cytometry panels
- Multicolor flow cytometry was performed to characterize TIL purity, identity, memory subset, activation, and exhaustion status
- Data were acquired from stained sample products on the FACS Canto II™ (BD Biosciences, Franklin Lakes, NJ) and ZE5 (Bio-Rad, Hercules, CA) cell analyzers

Cellular REDOX State


- Reactive oxygen species (ROS) are thought to have effects on T-cell function and proliferation; low concentrations of ROS in T-cells are a prerequisite for cell survival, and increased ROS accumulation can lead to apoptosis/necrosis^{5,6}
- Final harvested TIL products were tested for apoptosis, cell cycle, proliferation, metabolic by-product, and mitochondrial function
 - Late-stage apoptosis was measured by staining the final TIL product using Annexin-V and 7AAD (7-aminoactinomycin D) antibody staining
 - Cell cycle stage was measured using FxCycle™ PI/RNase Staining Solution kit (ThermoFisher)
 - Cell proliferation was measured using MTT reagents on harvested TIL products that were rested and incubated with or without IL-2 for 6 days
 - Metabolic by-products (lactate) were measured in the spent media on days 11, 16, and 22
 - MitoSOX™ (mitochondrial morphology and reactive oxygen species, ThermoFisher), MitoTracker™ Green (dysfunctional mitochondria, ThermoFisher) or MitoTracker Red (functional mitochondria, ThermoFisher) were determined using flow cytometry

TCR Clonotypes

- Final harvested TIL products were sampled and mRNA was isolated for TCR V-beta deep sequencing performed at iRepertoire, Inc. (Huntsville, AL)

Results


Figure 2. Viable Cell Dose, Purity, Identity, and Potency of the TIL Product



P-values represent the difference between G-Rex and EXP-Pak condition using student's unpaired T test (*, P<0.05). Mean ± SD are displayed.

- All of the harvested TIL products met the release criteria for viable cell dose, purity (% viability), identity (%CD45⁺CD3⁺), and potency (IFN γ release)


Figure 3. TIL Purity, Identity, Memory, and Differentiation



Memory subsets were identified based on the levels of CD45RA and CCR7. Mean ± SD are displayed. TEMRA=CD45RA⁺ effector memory (CD45RA⁺, CCR7⁻), TN=naïve (CD45RA⁺, CCR7⁻), TCM=central memory (CD45RA⁺, CCR7⁺), TEM=effector memory (CD45RA⁺, CCR7⁺).

- In both G-Rex and EXP-Pak conditions, few contaminating non-T-cell (NK cells, B cells, and monocytes) immune populations were observed
- TIL generated in both conditions predominantly expressed TCR α/β with lesser TCR γ/δ
- The ratios of CD4⁺ and CD8⁺ populations were comparable in both conditions
- Majority of TIL displayed effector memory phenotype and exhibited less differentiated status in both conditions


Figure 4. TIL Activation and Exhaustion Status



Statistical significance between G-Rex and EXP-Pak condition was determined using student's unpaired T test (*, P<0.05).

- No difference was observed in activation and exhaustion status TIL between the G-Rex and EXP-Pak conditions


Figure 5. Cellular REDOX State was Measured by Apoptosis, Cell Cycle, Proliferation, Metabolic By-Product, and Glucose Uptake



P-values represent the difference between G-Rex and EXP-Pak condition using student's unpaired T-test (*, P<0.05). Mean ± SD are displayed.

- Cellular REDOX state was comparable for the G-Rex and EXP-Pak conditions

Figure 6. Mitochondrial Function of TIL



- Mitochondrial function was comparable for TIL grown in G-Rex and EXP-Pak conditions

Figure 7. Summary of Final TIL Product TCR V-beta Clonotype and Frequency Distribution

A		Number of Common uCDR3 (% Overlap)	
		D22 G-Rex	D22 EXP-Pak
Run 1	D22 G-Rex	10584 (100)	5784 (97,* 91) ¹
	D22 EXP-Pak	- [†]	20212 (100)
Run 2	D22 G-Rex	11701 (100)	4607 (93,* 96) ¹
	D22 EXP-Pak	- [†]	14934 (100)
Run 3	D22 G-Rex	3792 (100)	2122 (99,* 99) ¹
	D22 EXP-Pak	- [†]	4172 (100)

[†]Percentage of uCDR3 clones in G-Rex found in EXP-Pak condition.
¹Percentage of uCDR3 clones in EXP-Pak found in G-Rex condition.
²Not applicable.




Figure shows frequencies of the most abundant 20 clones in each of the samples.

- 91% – 99% of TCR clones of TIL produced from EXP-Pak bags were present in TIL produced from G-Rex flasks
- Frequency distribution of the top 20 clones was similar between G-Rex and EXP-Pak conditions

Conclusions

- The final TIL product generated in EXP-Pak bags did not differ in growth, functionality, or phenotype compared with cells produced in G-Rex flasks
- TIL cellular REDOX state and mitochondrial function were comparable between both conditions
- TCR V-beta clonal diversity, sequence, and frequency of all comparability samples showed a high degree of similarity between both conditions
- These data support further evaluation of EXP-Pak or similar static gas-permeable cell culture bags for potential use in clinical and commercial TIL cell therapy manufacturing applications

References
1. Sarnaik AA, et al. *J Clin Oncol* (2021);39(24):2656–2666. doi: 10.1200/JCO.21.00612.
2. Thomas SS, et al. *J Clin Oncol* (2021);39 (suppl; abstract 9537).
3. Jazaeri A, et al. *J Clin Oncol* (2019);37 (suppl; abstract 2538).
4. Jimeno A, et al. *J Immunother Cancer* (2020);8 (suppl; abstract A378).
5. Kesavani P, et al. *Antioxid Redox Signal* (2013);18(12):1497–1534. doi: 10.1089/ars.2011.4073.
6. Redza-Dutoir M, et al. *Biochim Biophys Acta* (2016);1863(12):2977–2992. doi: 10.1016/j.bbmr.2016.09.012.

Abbreviations
2-NBDG, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose; DAPI, 4',6-diamidino-2-phenylindole; GMP, good manufacturing process; IFN, interferon; IL-2, interleukin-2; MHC, major histocompatibility complex; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NK, natural killer; REDOX, reduction/oxidation; REP, rapid expansion protocol; ROS, reactive oxygen species; TCM, central memory T-cells; TCR, T-cell receptor; TEM, effector memory T-cells; TEMRA, effector memory RA⁺ T-cells; TIL, tumor-infiltrating lymphocytes; TVC, total viable cells; uCDR3, unique CDR3.

Acknowledgements
• The authors would like to thank the participating patients and their families for donation of material used in this study
• This study was sponsored by Iovance Biotherapeutics, Inc. (San Carlos, CA)
• Graphics support was provided by Cognition Studio, Inc. (Seattle, WA) and funded by Iovance

Disclosures
• All authors meet the criteria for authorship set forth by the International Committee of Medical Journal Editors
• All authors are employees of Iovance and may have stock options